InflaRx decimated as IFX-1 fails in inflammatory skin disorder trial

6 June 2019

Germany-headquartered clinical-stage biotech InflaRx (Nasdaq: IFRX) saw its shares crash nearly 92% to $3.06 by close of trading on Wednesday, after the company revealed that IVX-1, its potential treatment for an inflammatory skin disorder, failed to demonstrate statistical significance compared to placebo.

It reported the top-line results of the international SHINE Phase IIb study, investigating the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody and the firm’s lead candidate, in patients suffering from moderate to severe hidradenitis suppurativa (HS), a painful and debilitating chronic inflammatory skin disease with limited treatment options.

Showed no significant dose response

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK